Logarithmic Mean Divisia Index Decomposition of CO2 Emissions from Urban Passenger Transport: An Empirical Study of Global Cities from 1960–2001

The urban transport sector has become one of the major contributors to global CO2 emissions. This paper investigates the driving forces of changes in CO2 emissions from the passenger transport sectors in different cities, which is helpful for formulating effective carbon-reduction policies and strategies. The logarithmic mean Divisia index (LMDI) method is used to decompose the CO2 emissions changes into five driving determinants: Urbanization level, motorization level, mode structure, energy intensity, and energy mix. First, the urban transport CO2 emissions between 1960 and 2001 from 46 global cities are calculated. Then, the multiplicative decomposition results for megacities (London, New York, Paris, and Tokyo) are compared with those of other cities. Moreover, additive decomposition analyses of the 4 megacities are conducted to explore the driving forces of changes in CO2 emissions from the passenger transport sectors in these megacities between 1960 and 2001. Based on the decomposition results, some effective carbon-reduction strategies can be formulated for developing cities experiencing rapid urbanization and motorization. The main suggestions are as follows: (i) Rational land use, such as transit-oriented development, is a feasible way to control the trip distance per capita (ii) fuel economy policies and standards formulated when there are oil crisis are effective ways to suppress the increase of CO2 emissions, and these changes should not be abandoned when oil prices fall and (iii) cities with high population densities should focus on the development of public and non-motorized transport. Document type: Articl

Overexpression of the FBA and TPI genes promotes high production of HDMF in Zygosaccharomyces rouxii

4-Hydroxy-2,5-dimethyl-3 (2H)-furanone (HDMF) is widely used in the food industry as a spice and flavoring agent with high market demand. In this study, fructose-1,6-bisphosphate aldolase (FBA) and triose phosphate isomerase (TPI) were overexpressed in Zygosaccharomyces rouxii in the form of single and double genes, respectively, via electroporation. High-yield HDMF-engineered yeast strains were constructed by combining the analysis of gene expression levels obtained by real-time fluorescence quantitative PCR technology and HDMF production measured by HPLC. The results showed that there was a significant positive correlation between the production of HDMF and the expression levels of the FBA and TPI genes in yeast; the expression levels of the FBA and TPI genes were also positively correlated (p < 0.05). Compared with the wild type (WT), the engineered strains F10-D, T17-D, and TF15-A showed marked increases in HDMF production and FBA and TPI gene expression (p < 0.05) and exhibited great genetic stability with no obvious differences in biomass or colony morphology. In addition, the exogenous addition of d-fructose promoted the growth of Z. rouxii. Among the engineered strains, when fermented in YPD media supplemented with d-fructose for 5 days, TF15-A (overexpressing the FBA and TPI genes) generated the highest HDMF production of 13.39 mg/L, which is 1.91 times greater than that of the wild-type strain. The results above indicated that FBA and TPI, which are key enzymes involved in the process of HDMF biosynthesis by Z. rouxii, positively regulate the synthesis of HDMF at the transcriptional level. d-fructose can be used as a precursor for the biosynthesis of HDMF by engineered yeast in industrial production

Rare Earth Ion Doped Luminescent Materials: A Review of Up/Down Conversion Luminescent Mechanism, Synthesis, and Anti-Counterfeiting Application

With the rapid development of modern technology and information systems, optical anti-counterfeiting and encryption have recently attracted considerable attention. The demand for optical materials is also constantly increasing, with new requirements proposed for performance and application fields. Currently, rare earth ion doped materials possess a unique electronic layer structure, underfilled 4f5d electronic configuration, rich electronic energy level, and long-life excited state, which can produce a variety of radiation absorption and emission. The distinctive properties of rare earth are beneficial for using in diverse optical output anti-counterfeiting. Design is essential for rare earth ion doped materials with multiple responsiveness and multi-channel optical information anti-counterfeiting in the field of information security. Therefore, this mini review summarizes the luminescent mechanisms, preparation methods, performance characteristics and anti-counterfeiting application of rare earth doped materials. In addition, we discuss some critical challenges in this field, and potential solutions that have been or are being developed to overcome these challenges

A Second-Generation Oral SARS-CoV‑2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the in vitro pan-human coronavirus antiviral activity and off-target selectivity profile of PF-07817883. PF-07817883 also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir. The preclinical in vivo pharmacokinetics and metabolism studies in human matrices are suggestive of improved oral pharmacokinetics for PF-07817883 in humans, relative to nirmatrelvir. In vitro inhibition/induction studies against major human drug metabolizing enzymes/transporters suggest a low potential for perpetrator drug–drug interactions upon single-agent use of PF-07817883

A Second-Generation Oral SARS-CoV‑2 Main Protease Inhibitor Clinical Candidate for the Treatment of COVID-19

Despite the record-breaking discovery, development and approval of vaccines and antiviral therapeutics such as Paxlovid, coronavirus disease 2019 (COVID-19) remained the fourth leading cause of death in the world and third highest in the United States in 2022. Here, we report the discovery and characterization of PF-07817883, a second-generation, orally bioavailable, SARS-CoV-2 main protease inhibitor with improved metabolic stability versus nirmatrelvir, the antiviral component of the ritonavir-boosted therapy Paxlovid. We demonstrate the in vitro pan-human coronavirus antiviral activity and off-target selectivity profile of PF-07817883. PF-07817883 also demonstrated oral efficacy in a mouse-adapted SARS-CoV-2 model at plasma concentrations equivalent to nirmatrelvir. The preclinical in vivo pharmacokinetics and metabolism studies in human matrices are suggestive of improved oral pharmacokinetics for PF-07817883 in humans, relative to nirmatrelvir. In vitro inhibition/induction studies against major human drug metabolizing enzymes/transporters suggest a low potential for perpetrator drug–drug interactions upon single-agent use of PF-07817883